×
Inventiva S.A Price to Free Cash Flow Ratio 2020-2023 | IVA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Inventiva S.A price to free cash flow ratio from 2020 to 2023. Price to free cash flow ratio can be defined as
View More
Inventiva S.A Price to Free Cash Flow Ratio 2020-2023 | IVA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Inventiva S.A price to free cash flow ratio from 2020 to 2023. Price to free cash flow ratio can be defined as
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$171.5B
Vertex Pharmaceuticals (VRTX)
$119.5B
Regeneron Pharmaceuticals (REGN)
$114.6B
Gilead Sciences (GILD)
$103.4B
Bristol Myers Squibb (BMY)
$101.6B
CSL (CSLLY)
$97.4B
GSK (GSK)
$84.8B
Alnylam Pharmaceuticals (ALNY)
$35.2B
Argenex SE (ARGX)
$31.4B
Biogen (BIIB)
$28.2B
BioNTech SE (BNTX)
$28B
Moderna (MRNA)
$24.6B
Illumina (ILMN)
$21.1B
BeiGene (BGNE)
$20.7B
Genmab (GMAB)
$16B
BioMarin Pharmaceutical (BMRN)
$13.3B
Exact Sciences (EXAS)
$12.6B
Incyte (INCY)
$12.5B
Insmed (INSM)
$12.5B
Vaxcyte (PCVX)
$12.4B
Bio-Techne Corp (TECH)
$12.4B
Sarepta Therapeutics (SRPT)
$11.9B
QIAGEN (QGEN)
$10.3B
Bio-Rad Laboratories (BIO.B)
$9.1B
Ascendis Pharma (ASND)
$8.6B
Roivant Sciences (ROIV)
$8.6B
Legend Biotech (LEGN)
$8.5B
Repligen (RGEN)
$8.2B
Intra-Cellular Therapies (ITCI)
$7.7B
Exelixis (EXEL)
$7.5B